BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27774774)

  • 1. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
    Pericay C; Rivera F; Gomez-Martin C; Nuñez I; Cassinello A; Imedio ER
    Cancer Med; 2016 Dec; 5(12):3464-3474. PubMed ID: 27774774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of ramucirumab in gastroesophageal adenocarcinoma.
    Elimova E; Lin Q; Song S; Ajani JA
    Future Oncol; 2017 Aug; 13(18):1585-1592. PubMed ID: 28436242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 6. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
    Tabernero J; Bang YJ; Van Cutsem E; Fuchs CS; Janjigian YY; Bhagia P; Li K; Adelberg D; Qin SK
    Future Oncol; 2021 Aug; 17(22):2847-2855. PubMed ID: 33975465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
    Hofheinz RD; Lorenzen S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
    Tehfe M; Tabchi S; Laterza MM; De Vita F
    Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
    Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
    Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
    Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
    Janmaat VT; Steyerberg EW; van der Gaast A; Mathijssen RH; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004063. PubMed ID: 29182797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second-line treatment for metastatic or locally advanced gastric cancer].
    Li KC; Cheng SY; Du J; Li J
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):721-724. PubMed ID: 27784452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X; Zhou L; Zhou C; Shen L
    Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
    Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
    Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.